1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint.
(
- Contribution to journal › Article
-
Mark
Automatic segmentation of myocardium at risk from contrast enhanced SSFP CMR: validation against expert readers and SPECT.
(
- Contribution to journal › Article
-
Mark
Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction
(
- Contribution to journal › Article
-
Mark
The Authors Reply
(
- Contribution to journal › Letter
-
Mark
Extent of myocardium at risk for left anterior descending artery, right coronary artery, and left circumflex artery occlusion depicted by contrast-enhanced steady state free precession and T2-weighted short tau inversion recovery magnetic resonance imaging
(
- Contribution to journal › Article
- 2015
-
Mark
Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results.
(
- Contribution to journal › Article
-
Mark
Contrast-Enhanced CMR Overestimates Early Myocardial Infarct Size: Mechanistic Insights Using ECV Measurements on Day 1 and Day 7.
(
- Contribution to journal › Article
-
Mark
Design of clinical cardioprotection trials using CMR : Impact of myocardial salvage index and a narrow inclusion window on sample size
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
Infarct quantification using 3D inversion recovery and 2D phase sensitive inversion recovery; validation in patients and ex vivo.
(
- Contribution to journal › Article